

**Guideline:** Colorectal Cancer (CRC) (update) Committee meeting 10

**Date:** 14<sup>th</sup> February 2019

**Location:** RCOG offices, London

**Minutes:** Final

<b>Committee members present:</b>	
Peter Hoskin (Chair)	(Present for notes 1–6)
Justin Davies (Topic Adviser)	(Present for notes 1–6)
Cindy Chew	(Present for notes 1–6)
Julie Hepburn	(Present for notes 1–6)
Jay Bradbury	(Present for notes 1–6)
Richard Roope	(Present for notes 1–6)
Kevin Monahan	(Present for notes 1–4)
Baljit Singh	(Present for notes 1–6)
Charlotte Dawson	(Present for notes 1–6)
Debby Lennard	(Present for notes 1–6)
Manuel Salto-Tellez	(Present for notes 1–6)

<b>In attendance:</b>		
Maija Kalioinen	NGA Guideline Lead	(Present for notes 1-6)
Palida Teelucknavan	NGA Project Manager	(Present for notes 1-6)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 1-6)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for notes 1-6)
Audrey Tan	NGA Systematic Reviewer	(Present for notes 1-6)
Ted Barker	NGA Systematic Reviewer	(Present for notes 1-6)
Aghesa Mehmeti	NGA Information Scientist	(Present for notes 4-4)
Justine Karpusheff	NICE Guideline Commissioning Manager	(Present for notes 1-6)
Rachel Marshall	NGA Guideline Lead (observer)	(Present for notes 1-4)

<b>Apologies:</b>	
Vivek Misra	GC member
Michael Braun	GC member

<b>1. Welcome and objectives for the meeting</b>
<p>The Chair welcomed the Committee members and attendees to the 10<sup>th</sup> meeting on Colorectal Cancer guideline (update). The Committee members and attendees introduced themselves.</p> <p>The Chair informed the committee that apologies had been received as noted above.</p> <p>The Chair outlined the objectives of the meeting, which included: Preliminary findings for review 2.1; presentation of evidence for reviews 3.2, 3.3; results of the health economic modelling for 4.3b1 and 4.3b2; a review of the draft research recommendations and prioritisation of search re-runs.</p>
<b>2. Confirmation of matter under discussion, and declarations of interest</b>
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter</p>

under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Justin Davies	Committee member & Topic Advisor (Colorectal Surgeon)	Chair of scientific session and presentation for Alpine Colorectal Meeting, Switzerland. Registration fee was waived for the meeting	Direct, non-financial	Declare and participate
Julie Hepburn	Committee Lay Member	Member of Project Team for Chronic Cancer Pain research (PhD Project UWE)	Direct, financial	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Minutes of last meeting**

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

### **4. Presentations**

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, who gave a presentation on Review Question 3.2 'Which people with early colon cancer can be treated with endoscopic resection alone?'

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Nathan Bromham for their presentation.

The Chair introduced Audrey Tan, NGA Systematic Reviewer, who gave a presentation on Review Question 3.3 'Which people with non-metastatic colon cancer would benefit from preoperative chemotherapy?'

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Audrey Tan for their presentation.

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, who gave a presentation on the preliminary findings for Review Question 2.1 'Which predictive biomarkers should be used in the systemic management of colorectal cancer patients?'. The full review will be presented at the next Committee meeting.

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Nathan Bromham for their presentation.

The Chair introduced Matthew Prettyjohns, NGA Senior Health Economist, who gave a presentation on the results of the economic modelling for Review Questions 4.3b1 'What is the optimal combination and sequence of treatments in patients presenting with metastatic colorectal cancer in the liver amenable to local treatment?' and 4.3b2 'What is the optimal combination and sequence of treatments in patients presenting with metastatic colorectal cancer in the liver not amenable to local treatment?'

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Matthew Prettyjohns for their presentation.

## **5. Questions and discussion**

The Committee discussed each presentation in relation to this guideline and were given the opportunity to ask questions. The Committee drafted recommendations based on the evidence heard.

The Committee agreed which evidence reviews should be updated with (potential) new evidence and the results of the re-runs will be presented at the final meeting in April.

The Committee reviewed the research recommendations drafted to date and agreed which should be prioritised.

## **6. Any other business**

There was no other business.

**Date of next meeting:** 21<sup>st</sup> March and 22<sup>nd</sup> March 2019

**Location of next meeting:** RCOG, London